Pfizer Corporation

Wyeth

Cornell University

Beth Israel Deaconess Medical Center, Inc.

Kimberly Ann Marquette

Lioudmila Tchistiakova

Geertruida Machteld Veldman

Xiang-Yang Tan

Kiran Khandke

Lisa Anne Collins-Racie

Christopher John Corcoran

Edward Roland Lavallie

Riyez Karim

John Adam Nowak

Nitin Krishnaji Damle

Davinder Gill

Arthur Kunz

Eric M Bennett

Erwin R Boghaert

Puja Sapra

Philip Ross Hamann

Hans-Peter Gerber

Jose William Saldanha

Samuel Goldman

Debra D Donaldson

Edmund Graziani

Lori J Fitz

Angela Widom

Eric Feyfant

Laura Lin

John Francis DiJoseph

Kevin Delos Parris

Marion T Kasaian

Tania Shane

Kodangattil R Sreekumar

Amy Sze Pui Tam

Nancy L Wood

Lioudmila Gennadievna Tchistiakova

Chakrapani Subramanyam

Pavel Strop

Dangshe Ma

Nathan Higginson-Scott

Lewis C Cantley

Lidia Mosyak

Isaac J Rondon

Ruth E Gimeno

Valerie Calabro

Chao Bai Huang

Irina Apostolou

Jack Bikker

L Nathan Tumey

Chad Michael May

Janet E Paulsen

Andrea Therese Hooper

Brooke M Emerling

Sreekumar R Kodangattil

Frank Loganzo, Jr

Stephen P Soltoff

Cindy M Hodakoski

Brian Gaither Bates

Edward Christian Rosfjord

Georgios Poulogiannis

Hui Liu

Lioudmile Tchistiakova

Kiran Manohar Khandke

John Francis Dijoseph

Kodangattil Raman Sreekumar

The present disclosure provides materials and methods for CUB domain-containing protein 1 (CDCP1)-targeted therapy.

CDCP1 antibodies and antibody drug conjugates

The present invention provides antibodies and antibody-drug conjugates that bind to the extra domain B splice variant of fibronectin 1 and methods for preparing and using the same.

Anti-EDB antibodies and antibody-drug conjugates

The present invention is directed to antibodies, and antigen-binding portions thereof, engineered to introduce amino acids for site-specific conjugation. The invention relates to engineered antibody constant region (Fc, C&#x3b3;, C&#x3ba;, and C&#x3bb;) polypeptides, and portions thereof, and antibodies comprising the polypeptides. Further, the invention relates to Fc fusion proteins comprising an engineered Fc region. The invention also relates to methods and uses of the engineered antibodies and portions for, among other things, production of antibody-drug conjugate therapeutics.

Engineered antibody constant regions for site-specific conjugation and methods and uses therefor

The present invention provides site specific HER2 antibody drug conjugates and methods for preparing and using the same.

Site specific HER2 antibody drug conjugates

The present invention relates to engineered heteromultimeric proteins, and more specifically, to methods for producing and purifying heterodimeric proteins, such as bispecific antibodies and. Methods for producing and purifying such engineered heterodimeric proteins and their use in diagnostics and therapeutics are also provided. The present invention also relates to a humanized antibody that specifically binds human TrkB and methods for producing and using the antibody to, inter alia, treat a hearing loss disorder.

Bispecific antibodies

The disclosure provides novel molecules related to growth and differentiation factor-8 (GDF8), in particular epitopes specific to GDF8 and other specific antagonists of GDF8 in particular anti-GDF8 antibodies or antigen binding protein or fragment thereof which may inhibit GDF8 activity and signal in vitro and/or in vivo. The disclosure also provides for an immunoassay used to detect and quantitate GDF8. The disclosure also provides methods for diagnosing, preventing, ameliorating, and treating GDF8-associated disorders, e.g., degenerative orders of muscle, bone, and insulin metabolism. Finally, the disclosure provides pharmaceuticals for the treatment of such disorders by using the antibodies, polypeptides, polynucleotides, and vectors of the invention.

Antibody to GDF8 and uses thereof

Anti-5T4 antibodies, anti-5T4 antibody/drug conjugates, and methods for preparing and using the same.

Anti-5T4 antibodies and uses thereof

The disclosure provides novel molecules related to growth and differentiation factor 8 (GDF8), in particular epitopes specific to GDF8 and other specific antagonists of GDF8 in particular anti GDF8 antibodies or antigen binding protein or fragment thereof which may inhibit GDF8 activity and signal in vitro and/or in vivo. The disclosure also provides for an immunoassay used to detect and quantitate GDF8. The disclosure also provides methods for diagnosing, preventing, ameliorating, and treating GDF8 associated disorders, e.g., degenerative orders of muscle, bone, and insulin metabolism. Finally, the disclosure provides pharmaceuticals for the treatment of such disorders by using the antibodies, polypeptides, polynucleotides, and vectors of the invention.

Disclosed are anti-5T4 antibody drug conjugates and methods for preparing and using the same.

Antibody-drug conjugates

This application relates to antibodies, e.g., humanized antibodies, and antigen-binding fragments thereof, that bind to interleukin-13 (IL-13), in particular, human IL-13, and their uses in regulating immune responses mediated by IL-13. The antibodies disclosed herein are useful in diagnosing, preventing, and/or treating a subject, e.g., a human patient, one or more IL-13-associated disorders, e.g., respiratory disorders (e.g., asthma); atopic disorders (e.g., allergic rhinitis); inflammatory and/or autoimmune conditions of the skin (e.g., atopic dermatitis), and gastrointestinal organs (e.g., inflammatory bowel diseases (IBD)), as well as fibrotic and cancerous disorders.

Antibodies against human interleukin-13 and uses therefor

Growing community of inventors

Somerville, MA, United States of America

Kimberly Ann Marquette